{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:19:09Z","timestamp":1792081149647,"version":"4.4.0"},"reference-count":114,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) have revolutionized oncology, providing a groundbreaking therapeutic option for patients with various advanced-stage cancers. While these treatments can significantly extend survival, they also carry a substantial risk of immune-related adverse events, among which hypophysitis is particularly detrimental to endocrine function. This narrative review synthesizes current knowledge on the pathogenesis, clinical features, diagnosis, and management of ICI-induced hypophysitis (IH) based on an in-depth analysis of the recent literature and clinical trials. The diagnosis of IH presents unique challenges due to its overlap with systemic symptoms commonly associated with the underlying malignancy. These symptoms can include asthenia, anorexia, headache, vomiting, weight loss, hypotension, dizziness, decreased libido, and visual disturbances. Diagnostic evaluation typically combines clinical assessment, hormonal profiling, and findings from magnetic resonance imaging (MRI). Effective management of IH requires a personalized, multidisciplinary approach, focusing on hormone replacement therapy and vigilant monitoring. Long-term care depends on the severity of hypophysitis, and the specific hormonal axes involved. This review aims to enhance awareness of the critical aspects of recognizing and managing IH, underscoring the importance of early diagnosis and timely intervention to reduce its long-term effects on patient quality of life.<\/jats:p>","DOI":"10.3390\/cancers17030436","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T11:38:49Z","timestamp":1737977929000},"page":"436","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Immunotherapy-Related Hypophysitis: A Narrative Review"],"prefix":"10.3390","volume":"17","author":[{"given":"Vincenza","family":"Di Stasi","sequence":"first","affiliation":[{"name":"Center of Nutrition for the Research and the Care of Obesity and Metabolic Diseases, National Institute of Gastroentherology IRCCS Saverio De Bellis, 70013 Castellana Grotte, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"La Sala","sequence":"additional","affiliation":[{"name":"UOSD Malattie Endocrine Nutrizione e Ricambio, AORN, San Giuseppe Moscati, 83100 Avellino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Cozzi","sequence":"additional","affiliation":[{"name":"Endocrine Unit Grande Ospedale Metropolitano, Niguarda, 20162 Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Scavuzzo","sequence":"additional","affiliation":[{"name":"UOC Endocrinologia AORN A. Cardarelli, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0271-9858","authenticated-orcid":false,"given":"Vincenzo","family":"De Geronimo","sequence":"additional","affiliation":[{"name":"Centro Clinico Diagnostico GB Morgagni srl, 95125 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Poggi","sequence":"additional","affiliation":[{"name":"UOC Medicina Specialistica Endocrino-Metabolica, AOU Sant\u2019Andrea, 00189 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Vitale","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina, Chirurgia e Odontoiatria, Universit\u00e0 di Salerno, 84081 Baronissi, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Tortora","sequence":"additional","affiliation":[{"name":"UOC Clinica Endocrinologica e Diabetologica, AOU San Giovanni di Dio e Ruggi d\u2019Aragona, 84131 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/328267a0","article-title":"A new member of the immunoglobulin superfamily\u2014CTLA-4","volume":"328","author":"Brunet","year":"1987","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/er.2004-0011","article-title":"Autoimmune hypophysitis","volume":"26","author":"Caturegli","year":"2005","journal-title":"Endocr. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.bja.2019.11.034","article-title":"Immune checkpoint inhibitors: A narrative review of considerations for the anaesthesiologist","volume":"124","author":"Lewis","year":"2020","journal-title":"Br. J. Anaesth."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jaci.2009.12.980","article-title":"Overview of the immune response","volume":"125","author":"Chaplin","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13223-018-0278-1","article-title":"An introduction to immunology and immunopathology","volume":"14","author":"Marshall","year":"2018","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/1074-7613(94)90071-X","article-title":"CTLA-4 can function as a negative regulator of T cell activation","volume":"1","author":"Walunas","year":"1994","journal-title":"Immunity"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF02788753","article-title":"Role of the CTLA-4 receptor in T cell activation and immunity: Physiologic function of the CTLA-4 receptor","volume":"18","author":"Scheipers","year":"1998","journal-title":"Immunol. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.immuni.2016.04.020","article-title":"CD28 costimulation: From mechanism to therapy","volume":"44","author":"Esensten","year":"2016","journal-title":"Immunity"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: From T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Hossen, M.M., Ma, Y., Yin, Z., Xia, Y., Du, J., Huang, J.Y., Huang, J.J., Zou, L., Ye, Z., and Huang, Z. (2023). Current Understanding of CTLA-4: From Mechanism to Autoimmune Diseases. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1198365"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17446651.2019.1701434","article-title":"Hypophysitis induced by immune checkpoint inhibitors: A 10-year assessment","volume":"14","author":"Ippolito","year":"2019","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1158\/2326-6066.CIR-14-0040","article-title":"In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates","volume":"2","author":"Wang","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eprac.2020.11.004","article-title":"PD-L1 expression in normal endocrine tissues is not increased despite high incidence of PD-1 inhibitor-associated endocrinopathies","volume":"27","author":"Pollack","year":"2021","journal-title":"Endocr. Pract."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1007\/s00262-021-02955-y","article-title":"Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: A form of paraneoplastic syndrome","volume":"70","author":"Kanie","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41423-019-0232-2","article-title":"Hypothalamic expression of PD-L1: Does it mediate hypothalamitis?","volume":"16","author":"Iervasi","year":"2019","journal-title":"Cell. Mol. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","article-title":"Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade","volume":"170","author":"Wei","year":"2017","journal-title":"Cell"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.290.5489.84","article-title":"Immune inhibitory receptors","volume":"290","author":"Ravetch","year":"2000","journal-title":"Science"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/35105024","article-title":"T-cell regulation by CD28 and CTLA-4","volume":"1","author":"Alegre","year":"2001","journal-title":"Nat. Rev. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/rheumatology\/kez308","article-title":"Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors","volume":"58","author":"Weinmann","year":"2019","journal-title":"Rheumatology"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Chiloiro, S., Russo, F., Tartaglione, T., and Capoluongo, E.D. (2021). Molecular and Genetic Immune Biomarkers of Primary and Immune-Therapy Induced Hypophysitis: From Laboratories to the Clinical Practice. J. Pers. Med., 11.","DOI":"10.3390\/jpm11101026"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1200\/JCO.2016.69.1584","article-title":"Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients with Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer","volume":"35","author":"Beer","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-11-1595","article-title":"Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma","volume":"17","author":"Lipson","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/14737140.2018.1480942","article-title":"Nivolumab for the treatment of colorectal cancer","volume":"18","author":"Smith","year":"2018","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-Term Outcomes with Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients with Advanced Melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1080\/14712598.2020.1830056","article-title":"Pembrolizumab for the treatment of Hodgkin Lymphoma","volume":"20","author":"Lee","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1080\/14712598.2020.1792881","article-title":"Pembrolizumab for the treatment of esophageal cancer","volume":"20","author":"Yamamoto","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1080\/14737140.2021.1996228","article-title":"Pembrolizumab in the first-line treatment of advanced head and neck cancer","volume":"21","author":"Ferrarotto","year":"2021","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00262-020-02736-z","article-title":"Pembrolizumab and atezolizumab in triple-negative breast cancer","volume":"70","author":"Kwapisz","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1080\/14737140.2023.2247565","article-title":"Pembrolizumab for the adjuvant treatment of IIB or IIC melanoma","volume":"23","author":"Rutkowski","year":"2023","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): A multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1358\/dot.2017.53.12.2733054","article-title":"Durvalumab for the treatment of urothelial carcinoma","volume":"53","author":"Alsharedi","year":"2017","journal-title":"Drugs Today"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e002646","DOI":"10.1136\/jitc-2021-002646","article-title":"First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): Primary and biomarker analyses of a phase II study","volume":"9","author":"Mortier","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s40265-022-01723-1","article-title":"Nivolumab Plus Relatlimab: First Approval","volume":"82","author":"Paik","year":"2022","journal-title":"Drugs"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/eji.200323382","article-title":"The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells","volume":"33","author":"Workman","year":"2003","journal-title":"Eur. J. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.4049\/jimmunol.172.9.5450","article-title":"Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo","volume":"172","author":"Workman","year":"2004","journal-title":"J. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2004.08.010","article-title":"Role of LAG-3 in regulatory T cells","volume":"21","author":"Huang","year":"2004","journal-title":"Immunity"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.4049\/jimmunol.2001073","article-title":"Th17 cells contribute to the pathology of autoimmune hypophysitis","volume":"206","author":"Chalan","year":"2021","journal-title":"J. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.smim.2013.10.011","article-title":"Reasons for rarity of Th17 cells in inflammatory sites of human disorders","volume":"Volume 25","author":"Annunziato","year":"2013","journal-title":"Seminars in Immunology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"22246","DOI":"10.1073\/pnas.1908079116","article-title":"Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities","volume":"116","author":"Tahir","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1210\/clinem\/dgac161","article-title":"Endocrine autoantibodies determine immune checkpoint inhibitor-induced endocrinopathy: A prospective study","volume":"107","author":"Labadzhyan","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis secondary to cytotoxic T-lymphocyte\u2013associated protein 4 blockade: Insights into pathogenesis from an autopsy series","volume":"186","author":"Caturegli","year":"2016","journal-title":"Am. J. Pathol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/1479-5876-11-108","article-title":"The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-\u03b1 production","volume":"11","author":"Laurent","year":"2013","journal-title":"J. Transl. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1073\/pnas.1417320112","article-title":"Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients","volume":"112","author":"Romano","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","article-title":"Immunotherapy and hypophysitis: Clinical presentation, treatment, and biologic insights","volume":"19","author":"Faje","year":"2016","journal-title":"Pituitary"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Profili, N.I., Castelli, R., Gidaro, A., Merella, A., Manetti, R., Palmieri, G., Maioli, M., and Delitala, A.P. (2023). Endocrine side effects in patients treated with immune checkpoint inhibitors: A narrative review. J. Clin. Med., 12.","DOI":"10.3390\/jcm12155161"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e002493","DOI":"10.1136\/jitc-2021-002493","article-title":"Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors","volume":"9","author":"Kobayashi","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"101668","DOI":"10.1016\/j.beem.2022.101668","article-title":"Immune checkpoint inhibitor-related hypophysitis","volume":"36","author":"Mizukoshi","year":"2022","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr. Rev."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Chen, P., Li, J., and Tan, H. (2023). Progress and Challenges of Immune Checkpoint Inhibitor-Induced Hypophysitis. J. Clin. Med., 12.","DOI":"10.3390\/jcm12103468"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"101601","DOI":"10.1016\/j.beem.2021.101601","article-title":"Paraneoplastic autoimmune hypophysitis: An emerging concept","volume":"36","author":"Bando","year":"2022","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1507\/endocrj.EJ23-0050","article-title":"Paraneoplastic autoimmune hypophysitis: A novel form of paraneoplastic endocrine syndrome","volume":"70","author":"Takahashi","year":"2023","journal-title":"Endocr. J."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Bellastella, G., Carbone, C., Scappaticcio, L., Cirillo, P., Troiani, T., Morgillo, F., Vietri, M.T., Corte, C.M.D., De Falco, V., and Napolitano, S. (2021). Hypothalamic\u2013Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies. Cancers, 13.","DOI":"10.3390\/cancers13164036"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1210\/clinem\/dgaa771","article-title":"Hypothalamitis: A novel autoimmune endocrine disease. A literature review and case report","volume":"106","author":"Harput","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ejca.2018.09.016","article-title":"Hypothalamitis and severe hypothalamic dysfunction associated with anti\u2013programmed cell death ligand 1 antibody treatment","volume":"104","author":"Tshuma","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1210\/clinem\/dgab672","article-title":"Hypophysitis, the Growing Spectrum of a Rare Pituitary Disease","volume":"107","author":"Langlois","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s11102-021-01182-z","article-title":"Differences between immunotherapy-induced and primary hypophysitis\u2014A multicenter retrospective study","volume":"25","author":"Amereller","year":"2022","journal-title":"Pituitary"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Van Der Leij, S., Suijkerbuijk, K.P., van den Broek, M.F., Valk, G.D., Dankbaar, J.W., and Van Santen, H.M. (2024). Differences in checkpoint-inhibitor-induced hypophysitis: Mono-versus combination therapy induced hypophysitis. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1400841"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1080\/00325481.2019.1709344","article-title":"Immune checkpoint inhibitors and endocrine side effects, a narrative review","volume":"132","author":"Agrawal","year":"2020","journal-title":"Postgrad. Med."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Ferrari, S.M., Fallahi, P., Elia, G., Ragusa, F., Ruffilli, I., Patrizio, A., Galdiero, M.R., Baldini, E., Ulisse, S., and Marone, G. (2019). Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20102560"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"5411","DOI":"10.1038\/onc.2015.5","article-title":"Review of immune\u2013related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience","volume":"34","author":"Gao","year":"2015","journal-title":"Oncogene"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1158\/1078-0432.CCR-14-2353","article-title":"Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: A retrospective cohort study","volume":"21","author":"Min","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-12-0167","article-title":"Ipilimumab: A novel immunomodulating therapy causing autoimmune hypophysitis: A case report and review","volume":"167","author":"Juszczak","year":"2012","journal-title":"Eur. J. Endocrinol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s13181-021-00833-8","article-title":"A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors","volume":"17","author":"Chhabra","year":"2021","journal-title":"J. Med. Toxicol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: A comprehensive retrospective review from a single institution","volume":"21","author":"Ryder","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy\u2014Immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_74","first-page":"341","article-title":"Endocrine sequelae of immune checkpoint inhibitors","volume":"16","author":"Ntali","year":"2017","journal-title":"Hormones"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ando.2018.07.008","article-title":"Expert opinion on pituitary complications in immunotherapy","volume":"79","author":"Briet","year":"2018","journal-title":"Ann. Endocrinol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"bvad012","DOI":"10.1210\/jendso\/bvad012","article-title":"Spectrum of Clinical Presentations, Imaging Findings, and HLA Types in Immune Checkpoint Inhibitor-Induced Hypophysitis","volume":"7","author":"Quandt","year":"2023","journal-title":"J. Endocr. Soc."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2017.09.002","article-title":"Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials","volume":"119","author":"Hu","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis","volume":"4","author":"Barry","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/a-0843-3366","article-title":"A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors","volume":"51","author":"Andreescu","year":"2019","journal-title":"Horm. Metab. Res."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Almutairi, A.R., McBride, A., Slack, M., Erstad, B.L., and Abraham, I. (2020). Potential Immune-Related Adverse Events Associated with Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00091"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Da, L., Teng, Y., Wang, N., Zaguirre, K., Liu, Y., Qi, Y., and Song, F. (2020). Organ-Specific Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Monotherapy Versus Combination Therapy in Cancer: A Meta-Analysis of Randomized Controlled Trials. Front. Pharmacol., 10.","DOI":"10.3389\/fphar.2019.01671"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s11102-021-01141-8","article-title":"Isolated ACTH deficiency induced by cancer immunotherapy: A systematic review","volume":"24","author":"Iglesias","year":"2021","journal-title":"Pituitary"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.eprac.2022.04.010","article-title":"American Association of Clinical Endocrinology Disease State Clinical Review: Evaluation and Management of Immune Checkpoint Inhibitor-Mediated Endocrinopathies: A Practical Case-Based Clinical Approach","volume":"28","author":"Yuen","year":"2022","journal-title":"Endocr. Pract."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/EJE-14-0845","article-title":"Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma","volume":"172","author":"Albarel","year":"2015","journal-title":"Eur. J. Endocrinol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: A detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/cen.14349","article-title":"Clinical features and thyroid dysfunction in adverse events involving the pituitary gland during PD-1 blockade therapy","volume":"94","author":"Yamauchi","year":"2021","journal-title":"Clin. Endocrinol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13256-019-2002-2","article-title":"Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: A case report and review of the literature","volume":"13","author":"Ohara","year":"2019","journal-title":"J. Med. Case Rep."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1530\/EJE-19-0238","article-title":"Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis","volume":"181","author":"Faje","year":"2019","journal-title":"Eur. J. Endocrinol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e37587","DOI":"10.1097\/MD.0000000000037587","article-title":"The association of hypophysitis with immune checkpoint inhibitors use: Gaining insight through the FDA pharmacovigilance database","volume":"103","author":"Tang","year":"2024","journal-title":"Medicine"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.2217\/fon-2019-0101","article-title":"Cancer immunotherapy-associated hypophysitis","volume":"15","author":"Castillero","year":"2019","journal-title":"Future Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/ERC-18-0320","article-title":"French Endocrine Society Guidance on endocrine side effects of immunotherapy","volume":"26","author":"Castinetti","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.bulcan.2020.01.012","article-title":"Hypophysites induites par les immunoth\u00e9rapies anti-n\u00e9oplasiques [Checkpoint inhibitors-induced hypophysitis]","volume":"107","author":"Maillet","year":"2020","journal-title":"Bull. Cancer"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.radcr.2018.03.011","article-title":"Ipilimumab cystic hypophysitis mimicking metastatic melanoma","volume":"13","author":"Wallace","year":"2018","journal-title":"Radiol. Case Rep."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1530\/EC-20-0342","article-title":"Management of endocrine immune-related adverse events of immune checkpoint inhibitors: An updated review","volume":"9","year":"2020","journal-title":"Endocr. Connect."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.crad.2020.12.028","article-title":"The imaging of immunotherapy-related hypophysitis and other pituitary lesions in oncology patients","volume":"76","author":"Lasocki","year":"2021","journal-title":"Clin. Radiol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/jc.2012-4075","article-title":"Endocrine side effects induced by immune checkpoint inhibitors","volume":"98","author":"Corsello","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_98","first-page":"19","article-title":"Clinical heterogeneity of hypophysitis secondary to PD-1\/PD-L1 blockade: Insights from four cases","volume":"2019","author":"Lupi","year":"2019","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EC-18-0068","article-title":"Society for Endocrinology Endocrine Emergency Guidance: Acute management of the endocrine complications of checkpoint inhibitor therapy","volume":"7","author":"Higham","year":"2018","journal-title":"Endocr. Connect."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EC-16-0054","article-title":"Society For Endocrinology Endocrine Emergency Guidance: Emergency management of acute adrenal insufficiency (adrenal crisis) in adult patients","volume":"5","author":"Arlt","year":"2016","journal-title":"Endocr. Connect."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.amjmed.2015.08.021","article-title":"Adrenal Crisis: Still a Deadly Event in the 21st Century","volume":"129","author":"Puar","year":"2016","journal-title":"Am. J. Med."},{"key":"ref_103","unstructured":"Elshimy, G., Chippa, V., Kaur, J., and Jeong, J.M. (2023). Adrenal Crisis. StatPearls, StatPearls Publishing."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s40618-015-0301-z","article-title":"Ipilimumab-induced hypophysitis: Review of the literature","volume":"38","author":"Araujo","year":"2015","journal-title":"J. Endocrinol. Investig."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"6585","DOI":"10.1002\/cam4.2533","article-title":"Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma","volume":"8","author":"Kassi","year":"2019","journal-title":"Cancer Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"7953","DOI":"10.3390\/curroncol29100629","article-title":"Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients","volume":"29","author":"Tong","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","article-title":"Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade","volume":"13","author":"Downey","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1530\/EJE-17-0810","article-title":"The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma","volume":"178","author":"Scott","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/cen.13063","article-title":"Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: Clinical review","volume":"85","author":"Joshi","year":"2016","journal-title":"Clin. Endocrinol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/1078155217727142","article-title":"Immunotherapy-induced autoimmune hypophysitis","volume":"25","author":"Valecha","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1507\/endocrj.EJ19-0163","article-title":"Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: Clinical guidelines of the Japan Endocrine Society","volume":"66","author":"Arima","year":"2019","journal-title":"Endocr. J."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7861\/clinmed.2022-0429","article-title":"Immune checkpoint inhibitor-mediated hypophysitis: No place like home","volume":"23","author":"Cooksley","year":"2023","journal-title":"Clin. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/3\/436\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:37:24Z","timestamp":1759919844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/3\/436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":114,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["cancers17030436"],"URL":"https:\/\/doi.org\/10.3390\/cancers17030436","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,27]]}}}